The contract manufacturing market for Pharmaceuticals in China is projected to grow at an annualized rate of ~8.9%, till 2030
Roots Analysis has done a detailedstudy on China PharmaceuticalContract Manufacturing Services Market, 2020-2030, covering keyaspects of the industry and identifying key future growth opportunities.
To order this 200+page report, which features 85+ figures and 100+ tables, please visit ChinaPharmaceutical Contract Manufacturing Services Market, 2020-2030
Key Market Insights
§ Presently, over 100CMOs across the globe claim to have manufacturing facilities in China, offeringservices for pharmaceutical API, intermediates and FDF manufacturing
§ CMOs have establishedmanufacturing facilities across different regions of China; Eastern China hasemerged as a popular hub, serving as a base of operations for many contractservice providers
§ The current,installed manufacturing capacity of pharmaceutical CMOs in China is estimatedto be over 46 million liters; interestingly, capacity utilization has been observedto be ~75% over the last few years
§ Big pharma playershave also invested significantly in this region for initiatives related to the establishmentor expansion of R&D centers and manufacturing facilities focused onpharmaceutical products
§ Innovator companies are expected to continue outsourcing clinical andcommercial manufacturing operations to China-based CMOs; the contract servicesindustry in the region is likely to grow at a CAGR of ~8.9%
§ In the long-term, theprojected future opportunity is anticipated to be well distributed acrossvarious market segments, such as different types of products (APIs and FDFs),region (eastern china, southern china, western china) and others
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Outsourcingin the Pharmaceutical Industry
3.3. Overview of thePharmaceutical Contract Manufacturing
3.4. Evolution of thePharmaceutical Contract Manufacturing Industry
3.4.1. Traditional ContractManufacturing Organizations (CMOs)
3.4.2. ModernCMOs
3.5. Services Offered byCMOs
3.6. PharmaceuticalContract Manufacturing Scenario in China
3.7. Advantagesand Challenges associated with Outsourcing Pharmaceutical Manufacturing toChina-based CMOs
4. CASE STUDY: COMPARISON OF SMALL MOLECULES ANDLARGE MOLECULES
4.1. ChapterOverview
4.2. Small Molecule andLarge Molecule Drugs / Therapies
4.2.1. Comparison of GeneralCharacteristics
4.2.2. Comparisonof Manufacturing Processes
4.2.3. Comparisonof Key Manufacturing-related Challenges
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilitiesin China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysisby Company Size
5.2.3. Analysisby Location of Headquarters
5.2.4. Analysis by Type of Product (API andFDF)
5.2.5. Analysisby Type of FDF
5.2.6. Analysisby Type of Packaging
5.2.7. Analysis by Manufacturing Facilities
5.3. Non-ChinesePharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysisby Year of Establishment
5.3.2. Analysisby Company Size
5.3.3. Analysisby Location of Headquarters
5.3.4. Analysisby Type of Product (API and FDF)
5.3.5. Analysis by Type of FDF
5.3.6. Analysis by Type of Packaging
5.3.7 Analysis by Manufacturing Facilities
6. MANUFACTURING FACILITIES OFPHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Chinese Pharmaceutical CMOs: List of ManufacturingFacilities
6.2.1. Analysisby CMO Manufacturing Facilities in Eastern China
6.2.2. Analysisby CMO Manufacturing Facilities in Southern China
6.2.3. Analysisby CMO Manufacturing Facilities in Northern China
7. PHARMACEUTICAL MANUFACTURINGREGULATIONS IN CHINA
7.1. ChapterOverview
7.1.1. Health Authorities in China
7.1.2. Overviewof Regulatory Guidelines in China
8. COMPANY PROFILES
8.1. ChapterOverview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. China-based Manufacturing Facilitiesand Capabilities
8.2.4. Recent Developments and FutureOutlook
8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. China-based Manufacturing Facilitiesand Capabilities
8.3.4. Recent Developments and FutureOutlook
8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. China-based Manufacturing Facilitiesand Capabilities
8.4.4. Recent Developments and FutureOutlook
8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. China-based Manufacturing Facilitiesand Capabilities
8.5.4. Recent Developments and FutureOutlook
8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. China-based Manufacturing Facilitiesand Capabilities
8.6.4. Recent Developments and FutureOutlook
8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. China-based Manufacturing Facilitiesand Capabilities
8.7.4. Recent Developments and FutureOutlook
8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. China-based Manufacturing Facilitiesand Capabilities
8.8.4. Recent Developments and FutureOutlook
8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. China-based Manufacturing Facilitiesand Capabilities
8.9.4. Recent Developments and FutureOutlook
8.10. Shanghai AcebrightPharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. China-based Manufacturing Facilitiesand Capabilities
8.10.4. Recent Developments and Future Outlook
8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. China-based Manufacturing Facilitiesand Capabilities
8.11.4. Recent Developments and FutureOutlook
8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.3. China-based Manufacturing Facilitiesand Capabilities
8.12.4. Recent Developments and FutureOutlook
9. BIG PHARMA INITIATIVES IN CHINA
9.1. ChapterOverview
9.2. BigPharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year ofInitiative
9.2.4. Analysis by Type of Initiative
9.3. BenchmarkAnalysis of Big Pharma Players
9.3.1. Harvey Ball Analysis: Summary ofInvestments Made
9.3.2. Geographical Analysis by InvestmentsMade (Facility Specific)
10. RECENT TRENDS
10.1. ChapterOverview
10.2. CMOswith Manufacturing Facilities in China: List of Partnerships
10.3. Analysis by Year and Type ofPartnership
10.4. Logo Landscape of Key Partners
10.5. Geographical Analysis
11. CAPACITY ANALYSIS
11.1. ChapterOverview
11.2. KeyAssumptions and Methodology
11.3. CMOswith Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of ChineseManufacturing Facilities
11.3.2.1. CapacityAnalysis: Eastern China
11.3.2.2. CapacityAnalysis: Southcentral China
11.3.2.3. CapacityAnalysis: Northern China
12. SWOT ANALYSIS
12.1. ChapterOverview
12.2. Comparison of SWOT Factors
12.3. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing ServicesMarket in China, 2020-2030
13.4. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Distribution byGeography
13.4.1. Pharmaceutical ContractManufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical ContractManufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical ContractManufacturing Services Market in Northern China, 2020-2030
13.5. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Distribution byType of Product
13.5.1. API Contract Manufacturing ServicesMarket in China, 2020-2030
13.5.1.1. APIContract Manufacturing Services Market in China, 2020-2030: Distribution byGeography
13.5.1.1.1. APIContract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. APIContract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. APIContract Manufacturing Services Market in Northern China, 2020-2030
13.5.2. Drug Product Contract ManufacturingServices Market in China, 2020-2030
13.5.2.1. DrugProduct Contract Manufacturing Services Market in China, 2020-2030:Distribution by Geography
13.5.2.1.1. DrugProduct Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. DrugProduct Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. DrugProduct Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2.2. DrugProduct Contract Manufacturing Services Market in China, 2020-2030:Distribution by Type of Drug Product
13.5.2.2.1. DrugProduct Contract Manufacturing Services Market in China, 2020-2030: Share ofSolid Drug Product
13.5.2.2.2. DrugProduct Contract Manufacturing Services Market in China, 2020-2030: Share ofLiquid and Semi Solid Drug Product
13.5.2.2.3. DrugProduct Contract Manufacturing Services Market in China, 2020-2030: Share ofInjectable Drug Product
13.5.2.2.4. Drugproduct Contract Manufacturing Services Market in China, 2020-2030: Share ofOther Drug Products
13.6. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Distribution byScale of Operation
13.6.1. Clinical Scale ContractManufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale ContractManufacturing Services Market in China, 2020-2030
13.7. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Distribution bySize of Manufacturers
13.7.1. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Share of SmallCompanies
13.7.2. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Share of Mid-sizedCompanies
13.7.3. PharmaceuticalContract Manufacturing Services Market in China, 2020-2030: Share of Large /Very Large Companies
14. CASE STUDY: IMPACT OF CORONAVIRUSOUTBREAK
14.1. Chapter Overview
14.2. Current Opinions and RecuperativeInitiatives of Key Players
14.2.1. Wuxi AppTec
14.2.2. Porton Pharma Solutions
14.2.3. Lonza
14.3. Impact on Future Market Opportunity forPharmaceutical CMOs in China
15. CONCLUSION
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
